000623:SZSEJilin Aodong Pharmaceutical Group Co., Ltd. Analysis

Jilin Aodong Pharmaceutical trades at a **trailing P/E of 7.4**, dramatically below the industry average of 27.4, and a **price‑to‑book of 0.64**, suggesting a strong value tilt. The company generates a **2.89% dividend yield** with a modest **payout ratio of 21%**, and its balance sheet shows **cash (≈2.9 B CNY) exceeding debt (≈2.25 B CNY)** despite a high debt‑to‑equity ratio of 7.1. However, revenue has contracted **17.4% year‑over‑year**, operating margins are thin at **4.5%**, and ROE sits at only **8.8%**, indicating limited growth momentum. The DCF‑derived fair value of **≈1.38 CNY** is far below the current price of **17.3 CNY**, flagging a potential overvaluation relative to intrinsic estimates.
Technically, the stock is **below its 20‑day (18.21) and 50‑day (18.05) SMAs**, with a **bearish MACD** and an **RSI of 34.9**, hinting at lingering weakness. Volume is on a decreasing trend, and the price hovers just above the **support level of 17.19 CNY** while facing resistance near **19.2 CNY**. The low beta (0.41) and moderate 30‑day volatility (≈19.7%) suggest limited market‑wide risk, yet the sector faces **medium regulatory risk** and **medium geographic risk** given China’s pharma landscape. Overall, the stock appears cheap on multiples but overvalued by discounted cash‑flow, with mixed signals across fundamentals and technicals.